

Application No. 1010/629,368
Amendment dated August 29, 2006
Reply to Office Action of May 31, 2006

AUG 29 2006


Any Dkt No. 02-479-C

This listing of the claims will replace all prior versions, and listings, of claims in the application. At the request of the examiner, the Applicant has not included a clean copy of the amended claims as an Appendix to this Reply.

Please cancel claims 5, 16, 19, and 20. With the entry of this response, claims 1-4, 6-15, 17-18, and 21-30 will remain in this case.

LISTING OF THE CLAIMS


1. (Currently amended) A method of producing coronary vasodilation without significant peripheral vasodilation comprising administering by intravenous (iv) bolus at least 10 μ g of at least one A_{2A} receptor agonist selected from the group consisting of CVT-3146, named (1-{9-[4S,2R,3R,5R]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula:



CVT-3033, named (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9yl]-5-(hydroxymethyl)oxolane-3,4-diol, which has the formula:

Application No. 1010/629,368
Amendment dated August 29, 2006
Reply to Office Action of May 31, 2006

Atty Dkt No. 02-479-C



and combinations thereof to a human.

2. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount that does not exceed about 1000 µg.

3. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount ranging from about 10 to about 600 µg.

4. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in a single dose.

5. (Canceled)

6. (Currently amended) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount ranging from about 0.05 to about 60 µg/kg and wherein the A_{2A} receptor agonist is administered by ~~iv~~ intravenous (iv) bolus.

7. (Currently amended) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount ranging from about 0.1 to about 30 µg/kg wherein the A_{2A} receptor agonist is administered by ~~iv~~ intravenous (iv) bolus.

Application No. 1010/629,368
Amendment dated August 29, 2006
Reply to Office Action of May 31, 2006

Att'y Dkt No. 02-479-C

8. (Currently amended) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount no greater than about 20 µg/kg to a supine patient and wherein the A_{2A} receptor agonist is administered by ~~iv~~ intravenous (iv) bolus.

9. (Currently amended) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount no greater than about 10 µg/kg to a standing patient wherein the A_{2A} receptor agonist is administered by ~~iv~~ intravenous (iv) bolus.

10. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount ranging from about 10 to about 600 µg wherein the wherein the A_{2A} receptor agonist is administered in about 20 seconds.

11. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount ranging from about 10 to about 600 µg wherein the A_{2A} receptor agonist is administered in less than about 10 seconds.

12. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount greater than about 100 µg.

13. (Currently amended) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount no greater than 600 µg.

14. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount no greater than 500 µg.


15. (Original) The method of claim 1 wherein the A_{2A} receptor agonist is administered in an amount ranging from about 100 µg to about 500 µg.

16. (Canceled)


Application No. 1010/629,368
Amendment dated August 29, 2006
Reply to Office Action of May 31, 2006

Atty Dkt No. 02-479-C

17. (Currently amended) A method of myocardial perfusion imaging of a human, comprising administering a radionuclide and a an A_{2A} receptor agonist selected from the group consisting of CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula:



CVT-3033, named (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9yl]-5-(hydroxymethyl)oxolane-3,4-diol, which has the formula:



and combinations thereof to the human, wherein the administration of the A_{2A} receptor agonist causes at least a 2.5 fold increase in coronary blood flow that is achieved within about 1 minute from the administration of the A_{2A} receptor agonist, and wherein the myocardium is examined for areas of insufficient blood flow following administration of the radionuclide and the A_{2A} receptor agonist.

Application No. 1010/629,368
Amendment dated August 29, 2006
Reply to Office Action of May 31, 2006

Atty Dkt No. 02-479-C

18. (Original) The method of claim 17 wherein the myocardium examination begins within about 1 minute from the time the A_{2A} receptor agonist is administered.

19-20. (Canceled)

21. (Original) The method of claim 17 wherein the radionuclide and the A_{2A} receptor agonist are administered separately.

22. (Original) The method of claim 17 wherein the radionuclide and the A_{2A} receptor agonist are administered simultaneously.

23. (Original) The method of claim 17 wherein the administration of the A_{2A} receptor agonist causes at least a 2.5 fold increase in coronary blood flow for less than about 5 minutes.

24. (Original) The method of claim 17 wherein the administration of the A_{2A} receptor agonist causes at least a 2.5 fold increase in coronary blood flow for less than about 3 minutes.

25. (Currently amended) The method of claim 17 wherein the A_{2A} receptor agonist is CVT-3146 which is administered in an amount ranging from about 10 to about 600 µg in a single ~~iv~~ intravenous (iv) bolus.

26. (Currently amended) The method of claim 25 wherein CVT-3146 is administered in an amount ranging from about 100 to about 500 µg in a single ~~iv~~ intravenous (iv) bolus.

27. (Original) The method of claim 17 wherein the a A_{2A} receptor agonist is CVT-3146 which is administered in a single dose in an amount ranging from 10 to about 600 µg that is independent of the weight of the human being dosed.

28. (Original) The method of claim 27 wherein the dose is administered in about 30 seconds or less.

Application No. 1010/629,368
Amendment dated August 29, 2006
Reply to Office Action of May 31, 2006

Atty Dkt No. 02-479-C

29. (Original) The method of claim 27 wherein the dose is administered in about 20 seconds or less.

30. (Original) The method of claim 17 wherein the A_{2A} receptor agonist is administered in a single dose.